[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100544926":3},{"organization":4,"armGroups":7,"interventions":10,"overallOfficials":10,"centralContacts":27,"locations":33,"responsibleParty":50,"collaborators":52,"id":56,"slug":57,"hasResults":58,"nctId":59,"briefTitle":60,"officialTitle":61,"acronym":10,"eligibilityCriteria":62,"healthyVolunteers":58,"sex":63,"minAge":64,"maxAge":10,"enrollmentInfo":65,"targetDuration":10,"studyType":68,"phases":10,"briefSummary":69,"conditions":70,"keywords":10,"overallStatus":36,"whyStopped":10,"lastUpdateSubmitDate":75,"lastUpdatePostDateStruct":76,"startDateStruct":79,"completionDateStruct":81,"leadSponsor":83,"locationsCount":84},{"fullName":5,"class":6},"Ray Therapeutics, Inc.","INDUSTRY",[8,12,15,18,21,24],{"label":9,"type":10,"description":11,"interventionNames":10},"Retinitis Pigmentosa",null,"Up to 40 patients with Retinitis Pigmentosa",{"label":13,"type":10,"description":14,"interventionNames":10},"Choroideremia","Up to 40 patients with Choroideremia",{"label":16,"type":10,"description":17,"interventionNames":10},"Stargardt Macular Dystrophy (Stargardt Disease)","Up to 40 patients with Stargardt Macular Dystrophy also known as Stargardt Disease",{"label":19,"type":10,"description":20,"interventionNames":10},"Geographic Atrophy from Age-related Macular Degeneration","Up to 40 patients with Geographic Atrophy from Age-related Macular Degeneration",{"label":22,"type":10,"description":23,"interventionNames":10},"X-linked Retinoschisis","Up to 40 patients with X-linked Retinoschisis",{"label":25,"type":10,"description":26,"interventionNames":10},"Other Retinal Dystrophies","Up to 40 patients with other retinal dystrophies",[28],{"name":29,"role":30,"phone":31,"phoneExt":10,"email":32},"Shawn Yu, OD","CONTACT","949-264-3793","info@vr-ai.com",[34],{"facility":35,"status":36,"city":37,"state":38,"zip":39,"country":40,"countryCode":41,"cosmosGeoPoint":42,"geoPoint":47,"contacts":48},"Vision Research and Assessment Institute","RECRUITING","Irvine","California","92612","United States","US",{"type":43,"coordinates":44},"Point",[45,46],-117.82311,33.66946,{"lat":46,"lon":45},[49],{"name":29,"role":30,"phone":31,"phoneExt":10,"email":32},{"type":51,"investigatorFullName":10,"investigatorTitle":10,"investigatorAffiliation":10,"oldNameTitle":10,"oldOrganization":10},"SPONSOR",[53],{"name":54,"class":55},"The Vision Research and Assessment Institute (VRAI)","UNKNOWN","100544926","observational-study-to-assess-endpoint-operational-feasibility--measurement-properties-in-patients-with-retinal-degeneration-100544926",false,"NCT06375239","Observational Study to Assess Endpoint Operational Feasibility & Measurement Properties in Patients with Retinal Degeneration","Observational, Non-Interventional Study to Determine the Operational Feasibility and Measurement Properties of Endpoints in Patients with Retinal Degeneration","Inclusion Criteria:\n\n* Diagnosis of bilateral retinitis pigmentosa, choroideremia, Stargardt macular dystrophy, geographic atrophy from age-related macular degeneration, X-linked retinoschisis or other retinal dystrophies confirmed from previous eye examination records\n* Best-corrected visual acuity between 20\u002F70 and HM in at least one eye as tested with clinic-based visual acuity method\n* Reasonably fluent in English\n\nExclusion Criteria:\n\n* Cognitive impairment, memory loss or dementia sufficient in severity to preclude informed consent or in the opinion of the investigator would prevent satisfactory completion of some or all of the testing.\n* Any circumstance that in the opinion of the investigator, would interfere with participation in, or compliance with the study protocol\n* Current pregnancy as reported by patient","ALL","18 Years",{"count":66,"type":67},120,"ESTIMATED","OBSERVATIONAL","The Vision Research and Assessment Institute (VRAI) was established with the purpose of serving as a testing facility for efficacy endpoints for patients with Low Vision.\n\nThe mission of the VRAI is to enable the highest quality, standardized efficacy testing of patients with visual impairment.\n\nThe VRAI facilitates the development and refinement of existing endpoints specifically for testing patients with Low Vision.",[9,13,71,72,19,73,74],"Stargardt Macular Dystrophy","Stargardt Disease","X-lined Retinoschisis","Retinal Dystrophies","2025-01-06",{"date":77,"type":78},"2025-01-08","ACTUAL",{"date":80,"type":78},"2024-04-05",{"date":82,"type":67},"2026-04-30",{"name":5,"class":6},1]